RIGHTimeCPV: Improving Communication for Young People with Cancer
This study, called RIGHTimeCPV, is looking at a new way to help young people with cancer and their families talk about how their illness might affect their future. It's for patients aged 12 to 25 who have a type of cancer that is difficult to treat, with a 50% or less chance of survival, and are expected to have follow-up appointments over the next six months. The study aims to see if this new communication approach, which involves a 'communication preferences companion' (CPC) to help discuss your preferences with your doctor, is practical and helpful. We want to understand if it's easy to use and if patients, parents, and doctors find it acceptable. The study plans to enroll about 85 participants, including patients, parents, and doctors.
- Study design
- This interventional study plans to enroll about 85 participants, including patients, parents, and oncologists. It focuses on a new communication approach rather than a specific drug.
- What's involved
- You would identify a communication preferences companion (CPC). You and your CPC would meet, and your CPC would document your preferences. Then, you, your CPC, and your oncologist would attend your next disease re-evaluation visit together.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your participation will be assessed between 1-30 days after a disease re-evaluation visit and again 6 months after your final disease re-evaluation visit.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Erica C. Kaye, MD, MPH · PRINCIPAL_INVESTIGATOR · St. Jude Children's Research Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Feasibility of implementing the RIGHTimeCPV interventionBetween Day 1-30 after a Disease Reevaluation Visit (DRV) [participant specific] and again 6 months after the final DRV during study exit interviews [participant specific
Quantitative findings of feasibility will be assessed using the Feasibility of Intervention Measure (FIM). The FIM measure includes four itemized responses that are scored from one to five, such that one represents the lowest possible mean score and five the highest possible mean score. Feasibility is standardly considered to be achieved with a mean score ≥3 for this measure. Higher scores indicate greater perceived feasibility of the intervention.
- Acceptability of implementing the RIGHTimeCPV interventionBetween Day 1-30 after a Disease Reevaluation Visit (DRV) [participant specific] and again 6 months after the final DRV during study exit interviews [participant specific
Quantitative findings of acceptability will be assessed using the Acceptability of Intervention Measure (AIM). The AIM measure includes four itemized responses that are scored from one to five, such that one represents the lowest possible mean score and five the highest possible mean score. Acceptability is standardly considered to be achieved with a mean score ≥3 for this measure. Higher scores indicate greater perceived acceptability.
- Percentage of participants who engage in at least one cycle of intervention6 months after the final DRV during study exit interviews [participant specific
The percentages of participating patients, parents, and multidisciplinary clinicians who engage in at least one cycle of the intervention.